WPC
BIO icon

Wedmont Private Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wedmont Private Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-708
Closed -$333K – 499
2023
Q1 		$333K Buy
708
+54
+8% +$25.3K 0.04% 313
2022
Q4 		$274K Buy
654
+83
+15% +$33.5K 0.04% 356
2022
Q3 		$238K Sell
571
-267
-32% -$133K 0.05% 320
2022
Q2 		$415K Buy
+838
New +$436K 0.09% 163

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Wedmont Private Capital's BIO Position: Q2 2023 in Review

Wedmont Private Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 708 shares — an estimated $333K sold.

Wedmont Private Capital first reported a position in BIO in Q2 2022 and held it in 4 quarters. The position peaked at $415K in Q2 2022. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Wedmont Private Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Wedmont Private Capital sold 708 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $333K.
  • Wedmont Private Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 4 quarters.
  • Wedmont Private Capital's Bio-Rad Laboratories Class A position peaked at $415K in Q2 2022.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Wedmont Private Capital's 13F filing for Q2 2023, filed 17 Jul 2023.